fig2

Figure 2. ZEB2 overexpression was observed in EGFR-TKI-resistant NSCLC. (A) Volcano plots demonstrating the DEGs in HCC827 and HCC4006 cells before and after erlotinib resistance, respectively. ZEB2 is circled in the plots; (B) Heatmap demonstrating the relations between the 17 most highly upregulated DEGs after EGFR-TKI resistance in HCC827 and HCC4006 cells and markers expressed by M1 (IL12, IL1β, TNF, IL6) and M2 (CD163, IL10, MRC1) macrophages; (C) qRT-PCR analysis to determine the mRNA expression of ZEB2 in EGFR-TKI-sensitive or -resistant NSCLC tumor cells. Data represent results from three independent experiments; (D) Western blotting analysis to determine the protein expression of ZEB2 in EGFR-TKI-sensitive or -resistant NSCLC tumor cells. Representative protein bands and the average results from 3 independent experiments are shown; (E) Representative IHC images of ZEB2 expression and CD206⁺ M2-like phenotype TAM infiltration. Brown granules denote positive staining. Scale bar: 200 μm; (F) Average counting numbers of ZEB2-positive tumor cells in each field (400 ×) of paired EGFR-TKI-sensitive and -resistant NSCLC samples; (G) Average counting numbers of CD206⁺ M2-like phenotype TAMs per field (400 ×) in NSCLC samples with high versus low ZEB2 expression. ^*P < 0.05, ^***P < 0.0005, ^****P < 0.0001.